{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:29:45Z","timestamp":1773379785637,"version":"3.50.1"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to quantitatively compare the efficacy and safety of long-acting \u03b22-agonist (LABA)\/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) for the treatment of stable chronic obstructive pulmonary disease (COPD), especially in terms of their loss of efficacy in lung function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Randomized controlled clinical trials of LABA\/LAMA FDCs for the treatment of stable COPD were comprehensively searched for in public databases. Pharmacodynamic models were established to describe the time course of the primary outcome [trough forced expiratory volume in the first second (FEV\n                      <jats:sub>1<\/jats:sub>\n                      )]. Secondary outcomes [COPD exacerbations, St. George\u2019s Respiratory Questionnaire (SGRQ), Transition Dyspnoea Index (TDI), and rescue medication use] and safety outcomes [mortality, serious adverse events (SAEs), and withdrawals due to adverse events (AEs)] were also compared via a meta-analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 22 studies involving 16,486 participants were included in this study. The results showed that in terms of primary outcome (change from baseline in trough FEV\n                      <jats:sub>1<\/jats:sub>\n                      ), the efficacy of vilanterol\/umeclidinium was the highest, while the efficacy of formoterol\/aclidinium was the lowest, with a maximum effect value (E\n                      <jats:sub>max<\/jats:sub>\n                      ) of 0.185 L [95% confidence interval (CI): 0.173\u20130.197 L] and 0.119 L (95% CI: 0.103\u20130.135 L), respectively. The efficacy of other drugs, such as formoterol\/glycopyrronium, indacaterol\/glycopyrronium, and olodaterol\/tiotropium, were comparable, and their E\n                      <jats:sub>max<\/jats:sub>\n                      values were 0.150\u20130.177 L. Except for vilanterol\/umeclidinium, the other four LABA\/LAMA FDCs showed a certain degree of loss of efficacy. Compared with the efficacy at 2\u2009days, the trough FEV\n                      <jats:sub>1<\/jats:sub>\n                      (L) relative to baseline at 24\u2009weeks decreased by 0.029\u20130.041 L. In terms of secondary outcomes, the efficacy of different LABA\/LAMA FDCs was similar in TDI and rescue medication use. However, formoterol\/aclidinium was better in preventing the COPD exacerbations, while vilanterol\/umeclidinium was the best in terms of SGRQ. In addition, different LABA\/LAMA FDCs and placebo had similar safety outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The present findings may provide necessary quantitative information for COPD medication guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17534666211066068","type":"journal-article","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T06:30:56Z","timestamp":1641623456000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Quantitative analysis of efficacy and safety of LABA\/LAMA fixed-dose combinations in the treatment of stable COPD"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2415-8537","authenticated-orcid":false,"given":"Yiwen","family":"Gong","sequence":"first","affiliation":[{"name":"Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghua","family":"Lv","sequence":"additional","affiliation":[{"name":"Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, No. 1200 Cailun Road, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujin","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, No. 1200 Cailun Road, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"key":"bibr1-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00025805"},{"key":"bibr2-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-021-00153-w"},{"key":"bibr3-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.07.005"},{"key":"bibr4-17534666211066068","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2021 report, 2020, https:\/\/goldcopd.org\/wp-content\/uploads\/2020\/11\/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf (accessed 17 November 2020)."},{"key":"bibr5-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.02.646"},{"key":"bibr6-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30102-4"},{"key":"bibr7-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101855"},{"key":"bibr8-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00200212"},{"key":"bibr9-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00136014"},{"key":"bibr10-17534666211066068","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S171835"},{"key":"bibr11-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-14-178"},{"key":"bibr12-17534666211066068","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S81053"},{"key":"bibr13-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.242"},{"key":"bibr14-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.122"},{"key":"bibr15-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"bibr16-17534666211066068","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0, 2011, http:\/\/training.cochrane.org\/handbook (accessed 20 November 2020)."},{"key":"bibr17-17534666211066068","doi-asserted-by":"publisher","DOI":"10.4104\/pcrj.2012.00092"},{"key":"bibr18-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12606"},{"key":"bibr19-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011527125570"},{"key":"bibr20-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.05.016"},{"key":"bibr21-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.05.007"},{"key":"bibr22-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0131-2"},{"key":"bibr23-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01015-3"},{"key":"bibr24-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.11.028"},{"key":"bibr25-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70052-3"},{"key":"bibr26-17534666211066068","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S72482"},{"key":"bibr27-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-014-0123-0"},{"key":"bibr28-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70065-7"},{"key":"bibr29-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.06.001"},{"key":"bibr30-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.10.002"},{"key":"bibr31-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-1579"},{"key":"bibr32-17534666211066068","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S223638"},{"key":"bibr33-17534666211066068","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S102962"},{"key":"bibr34-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206345"},{"issue":"10","key":"bibr35-17534666211066068","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"Ferguson GT","year":"2018","journal-title":"Lancet Respir Med"},{"key":"bibr36-17534666211066068","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S125058"},{"key":"bibr37-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-15-78"},{"key":"bibr38-17534666211066068","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD), 2012, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/08\/WC500130880.pdf (accessed 7 March 2021)."},{"key":"bibr39-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1177\/1753465815624612"},{"key":"bibr40-17534666211066068","first-page":"51","volume":"11","author":"Kim SJ","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"bibr41-17534666211066068","first-page":"153","volume":"5","author":"Gladysheva ES","year":"2010","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"bibr42-17534666211066068","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105482"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666211066068","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666211066068","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666211066068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T18:31:33Z","timestamp":1740853893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666211066068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":42,"alternative-id":["10.1177\/17534666211066068"],"URL":"https:\/\/doi.org\/10.1177\/17534666211066068","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666211066068\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666211066068\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666211066068\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666211066068\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666211066068\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666211066068\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666211066068\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666211066068\/v2\/review1","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"17534666211066068"}}